A Multi-Cohort Phase 2 Dose-Escalation Study of ARQ 092 (Miransertib) in Proteus Syndrome
Learn more about:
Related Access Program
Related Clinical Trial
Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants
Study of Proteus Syndrome and Related Congenital Disorders
A Multi-Cohort Phase 2 Dose-Escalation Study of ARQ 092 (Miransertib) in Proteus Syndrome
Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies